Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$102.74-2.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RYTM
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||
| Revenues | 239.9 | 189.8 | 130.1 | 77.4 | 23.6 | 3.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | 0.0 | 0.0 |
| Cost of Revenues | 26.4 | 19.5 | 13.4 | 9.3 | 2.1 | 0.6 | — | — | — | — |
| Operating Expenses & Income | ||||||||||
| Selling, General & Admin | 240.9 | 194.9 | 144.3 | 117.5 | 92.0 | 68.5 | 46.1 | 36.6 | 28.1 | 9.5 |
| R&D Expenses | 173.2 | 167.3 | 238.0 | 135.0 | 108.6 | 104.1 | 90.5 | 109.5 | 50.3 | 22.9 |
| Operating Income | (200.6) | (192.0) | (265.5) | (184.4) | (179.2) | (170.1) | (136.6) | (146.0) | (78.4) | (32.4) |
| Earnings from Continuing Operations | ||||||||||
| Interest Expense | — | 20.6 | 20.6 | 13.9 | 5.2 | — | — | — | — | — |
| Interest & Investment Income | — | — | — | — | — | 0.4 | 2.6 | 5.3 | 4.4 | 0.6 |
| Other Non-Operating Income / Expenses | (3.6) | (4.0) | 5.2 | 0.2 | (2.0) | 100.4 | 2.6 | 5.3 | 4.4 | (1.3) |
| EBT, Incl. Unusual Items | (204.3) | (196.0) | (260.3) | (184.1) | (181.1) | (69.6) | — | — | — | — |
| Income Tax Expense | 1.1 | 0.5 | 0.3 | 0.6 | — | — | — | — | — | — |
| Net Income | ||||||||||
| Net Income | (9.0) | (196.5) | (260.6) | (0.2) | (0.2) | (0.1) | (134.0) | (140.7) | (74.1) | (33.7) |
| Per Share | ||||||||||
| Basic EPS | (0.13) | (3.11) | (4.34) | (3.20) | (3.47) | (1.40) | (3.04) | — | — | — |
| Diluted EPS | (0.13) | (3.11) | (4.34) | (3.20) | (3.47) | (1.40) | (3.04) | — | — | — |
| Revenue per Share | 3.50 | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 68.6 | 65.0 | 61.0 | 57.7 | 52.1 | 49.6 | 44.1 | — | — | — |
| Diluted Weighted Avg Shares | 68.6 | 65.0 | 61.0 | 57.7 | 52.1 | 49.6 | 44.1 | — | — | — |
| Supplemental | ||||||||||
| EBITDA | — | (191.5) | (264.8) | (183.5) | (178.3) | (169.2) | (135.9) | (145.2) | (78.0) | (32.2) |
| EBIT | (200.6) | (192.0) | (265.5) | (184.4) | (179.2) | (170.1) | (136.6) | (146.0) | (78.4) | (32.4) |
| Effective Tax Rate | -0.5% | — | — | -0.3% | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.